IN

Integrated Biopharma IncOOTC INBP Stock Report

Last reporting period 30 Jun, 2024

Updated 31 Oct, 2024

Last price

Market cap $B

0.008

Micro

Exchange

OOTC - OTC

INBP Stock Analysis

IN

Avoid

Based on Eyestock quantitative analysis, INBP`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

61/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-95.3 %

Greatly overvalued

Market cap $B

0.008

Dividend yield

Shares outstanding

29.95 B

Integrated BioPharma, Inc. engages in the manufacturing, distributing, marketing, and sales of vitamins, nutritional supplements, and herbal products. The company is headquartered in Hillside, New Jersey and currently employs 147 full-time employees. The Company’s business segments include Contract Manufacturing operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and Other Nutraceutical Businesses, which includes the operations of AgroLabs, Inc. (AgroLabs), which distributed healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers under brands: Peaceful Sleep, and Wheatgrass and other products introduced into the market using the AgroLabs name; The Vitamin Factory, IHT Health Products, Inc. (IHT), MDC Warehousing and Distribution, Inc., and Chem International, Inc. The Company’s customers are located in the United States and Luxembourg.

View Section: Eyestock Rating